Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Cell and Gene Meeting on the Mesa 2026
18 slides from Arovella Therapeutics's conference presentation, Oct 6, 2026
Slide 1: Arovella presents at the Cell and Gene Meeting in Phoenix, Arizona
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release For personal use only 6 October 2026 AROVELLA PRESENTS AT THE CELL AND GENE MEETING IN PHOENIX, ARIZONA Highlights: • Arovella is delivering an “Innovation Spotlight” presentation tomorrow at the Cell and Gene Meeting on the Mesa Aro
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: For personal use only About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat bloo
Slide 3: Innovation Spotlight
rsonal use only Innovation Spotlight October 2026
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 5: Investment highlights
Investment highlights CAR-iNKT platform designed to support multiple future therapies rsonal use only Structurally differentiated next-generation cell therapy Near-term clinical validation Platform scalability Pipeline expansion • FDA IND accepted • Off-the-shelf manufacturing • Blood cancers • Phas
Slide 6: CAR-T technology challenges vs ALA's off-the-shelf solution
CAR-T technology challenges ALA’s off-the-shelf Only treats the patient who supplied the T cells solution: Manufacturing & supply rsonal use only chain costs high, failures T cell can occur Each manufacturing T cell batch is patient-specific T cells can be compromised by disease T cell Limited centr
Slide 7: CAR-iNKT cells – a differentiated immune cell
CAR-iNKT cells – a differentiated immune cell Unique biology with potential to overcome core limitations of CAR-T Multiple ways to attack tumours rsonal use only ALLOGENEIC WITHOUT GENE EDITING Off-the-shelf solution; no gene editing required (preserves cell fitness) MULTIPLE WAYS TO KILL CANCER CEL
Slide 8: Overcoming limitations of existing cell therapies
Overcoming limitations of existing cell therapies CAR-iNKT cells are uniquely positioned for cell therapy applications rsonal use only Modality Key Limitations Arovella CAR-iNKT Advantage Autologous CAR-T Relies on fitness of patient’s own T cells Healthy donor cells with better fitness Comple
Slide 9: World-class CAR-iNKT manufacturing platform
World-class CAR-iNKT manufacturing platform Semi-automated process suitable for large-scale and late-phase clinical development rsonal use only Arovella Manufacturing Platform Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells to Vial and freeze Donor Bl
Slide 10: One platform: three value-creation pathways
One platform: three value-creation pathways Value creation via three workstreams rsonal use only Core platform: healthy-donor iNKT cells + modular CAR backbone + scalable manufacturing Blood cancer validation -> solid-tumour expansion -> autoimmunity expansion CD19+ blood CLDN18.2+ solid CD19+ autoi
Slide 11: ALA-101: an off-the-shelf solution for CD19+ blood cancers
ALA-101: an off-the-shelf solution for CD19+ blood cancers Phase 1 first-in-human study expected to commence next month rsonal use only Validated target with potential for FDA IND accepted for indication expansion CD19+ lymphomas and Possibility to expand into autoimmunity if phase 1 ALA-101 (CD19 C
Slide 12: ALA-101-001 Phase 1 study; Blood Cancer
ALA-101-001 Phase 1 study; Blood Cancer Study population Adults with relapsed/refractory NHL (DLBCL • FL • MZL • MCL) CD19-positive B cell cancers Leukaemia (CLL • HCL) Patient journey rsonal use only 1. Screening 2. Lymphodepletion 3. ALA-101 infusion 4. On-study follow-up 5. Long-term follow-up Co
Slide 13: ALA-105 (CLDN18.2 CAR-iNKT)
rsonal use only ALA-105 (CLDN18.2 CAR-iNKT) A clinically validated target that is expressed in several solid tumour types 11
Slide 14: An off-the-shelf solution for solid tumours
An off-the-shelf solution for solid tumours With ALA’s proprietary cytokine armouring rsonal use only Validated target with high unmet need Novel, proprietary Potential to target a broad range of cancers CLDN18.2-targeting CAR ALA-105 (CLDN18.2 CAR-iNKT) • gastric, pancreatic, esophageal, GEJC, ovar
Slide 15: Armouring CAR-iNKT cells
ARMOURING “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours rsonal use only IL-12-TM IL-12-TM (Armouring for Solid Tumours) iNKT cells IL-12-TM IL-12-TM is a modified version of IL-12 Expand more 10x more Superior with a membrane anchor that l
Slide 16: Arovella's novel CLDN18.2-targeting CAR is highly active
Arovella’s novel CLDN18.2-targeting CAR is highly active Potent cytotoxicity in iNKT cells improved by armouring with IL-12-TM Killing of Gastric and Pancreatic Cancer rsonal use only Gastric cancer cells Pancreatic cancer cells CLDN18.2 CAR in iNKT cells ALA-105 (CLDN18.2 CAR-iNKT) * * ** ** 100
Slide 17: Summary
Summary FDA-accepted Near-term clinical-stage company milestones rsonal use only ALA-101 entering human trials First patient dosing and initial clinical readouts Differentiated cell Multiple expansion therapy platform CAR-iNKT cells combine Arovella’s opportunities Blood cancers, autoimmunity, multi
Slide 18: Thank You
ASX:ALA rsonal use only Thank You Arovella Therapeutics Email: investor@arovella.com
Arovella Therapeutics — Cell and Gene Meeting on the Mesa 2026 on 6ix